Calcein assay: a high-throughput method to assess P-gp inhibition

References

• Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. (2006). Characterization of α-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 20:273–282.
   PubMed Web of Science ®Google Scholar
• Belli S, Elsener PM, Wunderli-Allenspach H, Krämer SD. (2009). Cholesterol-mediated activation of P-glycoprotein: Distinct effects on basal and drug-induced ATPase activities. J Pharm Sci 98:1905–1918.
   Google Scholar
• Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, Drewe J. (2005). P-glycoprotein and surfactants: Effect on intestinal talinolol absorption. Clin Pharmacol Ther 77:24–32.
   PubMed Web of Science ®Google Scholar
• Brown CD, Sayer R, Windass AS, Haslam IS, De Broe ME, D’Haese PC, Verhulst A. (2008). Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 233:428–438.
   PubMed Web of Science ®Google Scholar
• Bubik M, Ott M, Mahringer A, Fricker G. (2006). Rapid assessment of p-glycoprotein-drug interactions at the blood-brain barrier. Anal Biochem 358:51–58.
   Google Scholar
• Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, Lee CA. (2010). Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 7:398–411.
   PubMed Web of Science ®Google Scholar
• Dantzig AH, de Alwis DP, Burgess M. (2003). Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55:133–150.
   PubMed Web of Science ®Google Scholar
• Draheim V, Reichel A, Weitschies W, Moenning U. (2010). N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur J Pharm Sci 41:201–209.
   PubMed Web of Science ®Google Scholar
• de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. (2007). Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 96:2808–2817.
   PubMed Web of Science ®Google Scholar
• Eagling VA, Profit L, Back DJ. (1999). Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543–552.
   PubMed Web of Science ®Google Scholar
• EMA Guideline on the Investigation of Drug Interactions, 2010: EUROPEAN MEDICINES AGENCY (22 April 2010) Guideline on the Investigation of Drug Interactions (Online) Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf. Accessed on 10 Jan 2011.
   Google Scholar
• Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, Artursson P. (2006). Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269–277.
   PubMed Web of Science ®Google Scholar
• Elsby R, Surry DD, Smith VN, Gray AJ. (2008). Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140–1164.
   PubMed Web of Science ®Google Scholar
• FDA concept paper. (2004). Drug Interaction Studies—Study design, data analysis, and implications for dosing and labeling Preliminary Concept Paper presented at the Food and Drug Administration Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology Subcommittee meeting, November 3, 2004. Available online at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004–4079B1_04_Topic2-TabA.pdf Accessed on 10 Jan 2011.
   Google Scholar
• FDA Guidance for Industry. (2006). Guidance for industry, drug interaction studies—Study design, data analysis, and implications for dosing and labeling draft guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (September 2006) Clinical Pharmacology. Available online at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf Accessed on 10 Jan 2011.
   Google Scholar
• Gatlik-Landwojtowicz E, Aänismaa P, Seelig A. (2006). Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45:3020–3032.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV. (2000). Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol 173:203–214.
   Google Scholar
• Guo A, Marinaro W, Hu P, Sinko PJ. (2002). Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby Canine Kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 30:457–463.
   PubMed Web of Science ®Google Scholar
• Hamada A, Miyano H, Watanabe H, Saito H. (2003). Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307:824–828.
   PubMed Web of Science ®Google Scholar
• Holló Z, Homolya L, Davis CW, Sarkadi B. (1994). Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191:384–388.
   PubMed Web of Science ®Google Scholar
• Hsing S, Gatmaitan Z, Arias IM. (1992). The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 102:879–885.
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–670.
   PubMed Web of Science ®Google Scholar
• Hunter J, Hirst BH, Simmons NL. (1993). Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10:743–749.
   PubMed Web of Science ®Google Scholar
• Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgrén JJ, Mönkkönen J. (2005). Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci 26:266–279.
   PubMed Web of Science ®Google Scholar
• Korjamo T, Kemiläinen H, Heikkinen AT, Mönkkönen J. (2007). Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab Dispos 35:1574–1579.
   Google Scholar
• Lee CA, Cook JA, Reyner EL, Smith DA. (2010). P-glycoprotein related drug interactions: Clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 6:603–619.
   PubMed Web of Science ®Google Scholar
• Lee CA, Hillgren KM, Zhang L, Polli JW. (2011). Response from the International Transporter Consortium. Nat Rev Drug Discov 10:75.
   Google Scholar
• Litman T, Skovsgaard T, Stein WD. (2003). Pumping of drugs by P-glycoprotein: A two-step process? J Pharmacol Exp Ther 307:846–853.
   PubMed Web of Science ®Google Scholar
• Lowes S, Cavet ME, Simmons NL. (2003). Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 458:49–56.
   PubMed Web of Science ®Google Scholar
• Ma JD, Tsunoda SM, Bertino JS Jr, Trivedi M, Beale KK, Nafziger AN. (2010). Evaluation of in vivo P-glycoprotein phenotyping probes: A need for validation. Clin Pharmacokinet 49:223–237.
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. (2000). Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624–632.
   PubMed Web of Science ®Google Scholar
• Markoutsa E, Pampalakis G, Niarakis A, Romero IA, Weksler B, Couraud PO, Antimisiaris SG. (2011). Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur J Pharm Biopharm 77:265–274.
   PubMed Web of Science ®Google Scholar
• Maubon N, Le Vee M, Fossati L, Audry M, Le Ferrec E, Bolze S, Fardel O. (2007). Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 21:659–663.
   PubMed Web of Science ®Google Scholar
• Meyers MB, Scotto KW, Sirotnak FM. (1991). P-glycoprotein content and mediation of vincristine efflux: Correlation with the level of differentiation in luminal epithelium of mouse small intestine. Cancer Commun 3:159–165.
   PubMedGoogle Scholar
• Molnár J, Kars MD, Gündüz U, Engi H, Schumacher U, Van Damme EJ, Peumans WJ, Makovitzky J, Gyémánt N, Molnár P. (2009). Interaction of tomato lectin with ABC transporter in cancer cells: Glycosylation confers functional conformation of P-gp. Acta Histochem 111:329–333.
   Google Scholar
• Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, Chieli E. (2006). Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br J Pharmacol 148:682–687.
   PubMed Web of Science ®Google Scholar
• Pál A, Méhn D, Molnár E, Gedey S, Mészáros P, Nagy T, Glavinas H, Janáky T, von Richter O, Báthori G, Szente L, Krajcsi P. (2007). Cholesterol potentiates ABCG2 activity in a heterologous expression system: Improved in vitro model to study function of human ABCG2. J Pharmacol Exp Ther 321:1085–1094.
   PubMed Web of Science ®Google Scholar
• Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. (1999). Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206–1212.
   PubMed Web of Science ®Google Scholar
• Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620–628.
   PubMed Web of Science ®Google Scholar
• Pradaxa (dabigatran etexilate). Summary of product characteristics. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf last updated 03/2009. Accessed on 10 Jan 2011.
   Google Scholar
• PubChem database. (2006). ATP-binding cassette sub-family B member 1 (Homo sapiens), calcein AM assay. Natl Center Biotechnol Inf., Bethesda, MD, USA, PubChem: 2006. (Online) Available at: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2521 Accessed on 10 Jan 2011.
   Google Scholar
• Rajnai Z, Méhn D, Beéry E, Okyar A, Jani M, Tóth GK, Fülöp F, Lévi F, Krajcsi P. (2010). ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos 38:2000–2006.
   PubMed Web of Science ®Google Scholar
• Rasilez (aliskiren hemifumarate). Summary of product characteristics. (Online) Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000964/WC500047220.pdf last updated 03/2009. Accessed on 10 Jan 2011.
   Google Scholar
• Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab Dispos 34:786–792.
   PubMed Web of Science ®Google Scholar
• Rebello S, Leon S, Hariry S, Dahlke M, Jarugula V. (2011). Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. J Clin Pharmacol 51:218–228.
   PubMed Web of Science ®Google Scholar
• Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. (1992). Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267:4854–4858.
   PubMed Web of Science ®Google Scholar
• Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. (2003). Comparison of in vitro P-glycoprotein screening assays: Recommendations for their use in drug discovery. J Med Chem 46:1716–1725.
   PubMed Web of Science ®Google Scholar
• Seelig A. (2007). The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J Mol Neurosci 33:32–41.
   PubMedGoogle Scholar
• Shapiro AB, Ling V. (1997). Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130–137.
   PubMedGoogle Scholar
• Shi JG, Zhang Y, Yeleswaram S. (2011). The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nat Rev Drug Discov 10:75; author reply 75.
   Google Scholar
• Smalley J, Marino AM, Xin B, Olah T, Balimane PV. (2007). Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay. J Chromatogr B Analyt Technol Biomed Life Sci 854:260–267.
   PubMed Web of Science ®Google Scholar
• Szerémy P, Pál A, Méhn D, Tóth B, Fülöp F, Krajcsi P, Herédi-Szabó K. (2011). Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds. J Biomol Screen 16:112–119.
   Google Scholar
• Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, Garberg P, Sjöström B, Lundgren B, Artursson P. (2001). Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164–170.
   PubMed Web of Science ®Google Scholar
• Tang F, Horie K, Borchardt RT. (2002). Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:765–772.
   PubMed Web of Science ®Google Scholar
• Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J. (2005). The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys J 88:715–738.
   PubMed Web of Science ®Google Scholar
• von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K. (2009). A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol 379:11–26.
   PubMedGoogle Scholar
• Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. (2005). Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872–1874.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709–724.
   PubMed Web of Science ®Google Scholar